Venous Stents Market

Venous Stents Market Outlook (2022-2032)

The global venous stents market size was valued at US$ 1.08 Billion in 2022, and is projected to reach US$ 2.44 Billion by 2032, growing at a CAGR (Compound Annual Growth Rate) of 8.5% during the forecast period from 2022 to 2032.

Venous stent technologies are classified into Iliac vein stent technologies and Wallstent technologies. Revenue from Wallstent technologies is expected to increase at a higher CAGR of 9% during the next 10 years. The purpose of Wallstent technology is to treat a constricted vein in the upper pelvic area that extends to the groyne area (iliofemoral vein). The Wallstent system usually consists of two parts: a stent composed of braided metallic (elgiloy) wire and a catheter device for over-the-wire stent delivery.

When the iliofemoral vein becomes constricted due to a buildup of fibrous blood clots along the vein's lining after a deep vein thrombosis or when the vein becomes compressed between a bone and an artery above it, Wallstent solution is used to widen the vein again (iliofemoral compression). These disorders often restrict blood circulation from the leg, causing swelling and walking pain.

Metal mesh tubes called venous stents are placed in the veins to treat chronic symptoms of venous disorders. Arterial stents and venous stents serve the same purpose. They come in a range of styles and dimensions.

Most often, a venous catheter is used to deliver stents compressed and to their intended location. Some catheters require the help of an inflated balloon, while others are self-expanded. These stents maintain the blocked or constricted veins open by expanding against them. They are flexible implants that support the vascular walls in both peripheral and central veins. Venous stent placement is typically done by surgeons in bigger, major veins such as those in the legs, belly, and chest.

Most stents are very difficult to remove if required and simply remain in place once they are implanted. Some stents can also be coated or made to release drugs gradually over time.

Venous stent devices are used to treat conditions such as chronic deep vein thrombosis, post-thrombotic syndrome, May-Thurner syndrome, and hemodialysis/arteriovenous fistulae.

Key venous stent manufacturers are heavily investing in R&D to come up with advanced flexible venous stents to treat several venous diseases. The sales of venous stents are also projected to increase as a result of the increasing senior population with target disorders and the rising spending power of individuals on healthcare.

Report Attributes	Details
Venous Stents Market Size (2022E)	US$ 1.08 Billion
Forecasted Market Value (2032F)	US$ 2.44 Billion
Global Market Growth Rate (2022-2032)	8.5% CAGR
China Market Growth Rate (2022-2032)	12% CAGR
Japan Market Growth Rate (2022-2032)	6% CAGR
Germany Market Growth Rate (2022-2032)	7% CAGR
Key Companies Profiled	Becton, Dickinson Company Boston Scientific Corporation Cook Medical LLC Gore Medical Jotec GmbH OptiMed Medizinische Instrumente GmbH

Why is There Such High Demand for Venous Stents?

“Rising Worldwide Cases of Chronic Symptomatic Venous Diseases”

• Deep vein thrombosis affects 13% to 31% of patients receiving medical critical care, according to a research titled "Incidence of proximal deep vein thrombosis in medical critical care patients" that was published in Thrombosis Journal in February 2022.
• Further, it also states that 10.1% was the incidence proportion, while 5.7% was the prevalence.

According to statistics, there has been a significant increase in the patient base, which is anticipated to spur the demand for leg vein stent surgeries.

• Also, as per research called "Prevalence of Post Thrombotic Syndrome in a Cohort of Upper Extremity Vein Thrombosis" which was published in the January 2022 issue of the Journal of Vascular Surgery: Venous and Lymphatic Disorders, 14.1% of cases of upper extremity PTS (UE-PTS) were caused by upper extremity venous thrombosis (UEVT).

Thus, rising cases of chronic symptomatic venous diseases are expected to boost sales of venous stent systems.

“Rising Incidence of Cardiovascular Disorders”

Angioplasty is a minimally-invasive procedure, whether it includes vascular stenting or not. When an artery or vein is too narrow or obstructed, angioplasty is utilised to increase blood flow. Instead of an operating room, it is typically performed in an interventional radiology room.

Also, promising minimally-invasive treatment for restricted arteries is performed during percutaneous transluminal angioplasty. Furthermore, top manufacturers are attempting to use high-quality drug-eluting venous stents to achieve excellent healthcare outcomes.

The main drawbacks of coated or bare metal stents have been addressed by the development of drug-eluting stents (DES).

• The Eluvia drug-eluting vascular stent device from Boston Scientific is getting a marketing boost since it can treat difficult lesions with excellent results.

Global cases of chronic cardiovascular diseases are rising primarily due to the increasing world’s senior population, as older people are more prone to experience heart-related disorders. Another significant problem for healthcare is hypertension. Older persons have higher amounts of total serum cholesterol, which makes them more vulnerable to several cardiovascular diseases.

Furthermore, obesity is a significant global risk factor for several heart diseases. Obesity or being overweight causes an excessive or improper buildup of fat within the artery wall, which can result in coronary heart disease and other health problems. As a result, controlling obesity and losing weight are essential steps in preventing cardiovascular disease. Thus, the above-mentioned factors are fuelling the sales of venous stents.

Which Challenges are Faced by Venous Stent Manufacturers?

“Strict Regulations for Product Approval”

Strict rules and policies for medical device approvals by respective authorities are expected to slow the production of stents.

Recent documentation of unintended negative patient outcomes has prompted the recall of several venous procedure devices from the market.

• For instance, Vascular Solutions Inc. recalled approximately 7,000 units of their venture catheters in 2017 because the catheter tip had extra material that could have split during surgeries and caused blood clots.

To prevent any anomaly from arising during the trials, leading medical device manufacturers rigorously scrutinize and test each product in the lab. This reduces the effective shelf life of important surgical tools, thus restricting the long-term growth potential of venous stents.

Country-wise Analysis

What is Outlook for Venous Stent Sales in the United States?

“Production of Advanced Venous Stents by Top Companies”

The United States currently dominates the North American venous stents market. The existence of major firms and their use of cutting-edge medical technologies to manufacture stents are primarily responsible for the larger share.

In addition, a well-developed healthcare infrastructure and significant financial investments by the government in the healthcare sector are some of the major drivers boosting venous stents market growth. Furthermore, supportive government policies and a rise in research collaboration agreements are among the factors likely to boost demand for venous stents.

• Deep vein thrombosis (DVT) or pulmonary embolism (PE) may affect 900,000 individuals annually in the United States, according to the Centers for Diseases Control and Prevention in June 2022.
• One-third to fifty percent of patients who experience a DVT may experience long-term effects (post-thrombotic syndrome), which include edoema, pain, discoloration, and scaling in the affected leg.

Why is Demand for Venous Stents Surging in European Countries?

“Growing Prevalence of Heart-related Disorders in Europe”

The rising rate of the senior population coupled with increasing cases of cardiovascular disorders in European countries such as the U.K., Germany, and Italy is expected to increase sales of venous stents.

• According to British Heart Foundation, currently, more than 7 million people in the U.K. are living with cardiovascular diseases (CVDs).
• According to Max Planck Institute, CVDs are the most common cause of death in Germany, and more than 1 million people are living with CVDs in the nation.

Sales of venous stents in Germany are predicted to expand at a CAGR of 7% during the forecast period. Thus, rising incidences of cardiovascular disorders in European nations are expected to fuel demand for venous stents.

What’s Benefitting Manufacturers of Venous Stents in Japan & Korea?

“Rapidly Developing Healthcare Infrastructure & Innovations in Medical Devices”

Japan and South Korea are leading markets for venous stents, due to advancing healthcare infrastructure, increasing cases related to stress and hypertension, and rising incidences of heart attacks due to running lifestyle.

Manufacturers of venous stents are attracted to Japan and South Korea due to beneficial government policies towards healthcare. In recent years, Korean manufacturers are creating sophisticated medical gadgets in response to end-user requests to achieve maximum productivity.

Additionally, these producers are introducing advanced medical consumables for the efficient treatment of people with coronary disease, which is predicted to increase the demand for venous stents in South Korea.

Category-wise Analysis

For Which Disease Treatment are Venous Stents Most Widely Used?

“Sales of Venous Stents Highest for Chronic Deep Vein Thrombosis Treatment”

When a (thrombus) blood clot develops in one or even more deep veins in the body, commonly in the legs, is known as chronic deep vein thrombosis. Leg pain or edoema may be brought on by deep vein thrombosis.

In some cases, there are no obvious signs. The rising incidence of chronic deep vein thrombosis and new stent device introductions by the major market participants are the main factors boosting the demand for venous stents.

• A paper titled "Deep Vein Thrombosis" which was produced in the National Library of Medicine in August 2021 states that the incidence of DVT in lower limbs is 1 case per 1000 persons, with a prevalence rate of DVT predicted to be 80 cases per 100,000 people. In the US, venous thrombosis affects over 200,000 persons annually; pulmonary embolism aggravates 50,000 of these cases.
• Iliofemoral venous outflow blockage is now most usually treated with stenting, according to the research paper "Contralateral deep-vein thrombosis in lliac vein stenting - Incidence, etiology, and prevention" printed in the Indian Journal Vascular and Endovascular Surgery. Patients with post-thrombotic syndrome (PTS), which develops after a prior deep vein thrombosis, can use it to treat severe ulcer healing situations as well as the signs of ongoing pain and swelling.

Thus, the above-mentioned studies show that the rising prevalence of chronic deep vein thrombosis is boosting the production of venous stents.

Competitive Landscape

Major venous stent companies are concentrated on launching upgraded stents and innovation in technologies to accelerate sales growth.

• The Medtronic venous stent namely "Abre venous self-expanding stent system" has been approved by the US Food and Drug Administration (FDA) for use in October 2020. When a patient has symptomatic deep venous obstruction, also known as iliofemoral venous outflow obstruction, this device is suggested for treatment.
• The "S.M.A.R.T. RADIANZ Vascular Stent System" from Cordis, a self-expanding stent specially developed for radial peripheral operations, obtained FDA approval in March 2022. The S.M.A.R.T. RADIANZ Vascular Stent System makes it easier to accurately and effectively insert stents in the superficial femoral (SFA) and iliac arteries.

Key Segments of Venous Stents Industry Research

• By Application :

  • Leg
  • Chest
  • Abdomen
  • Arm

• By Disease Indication :

  • Chronic Deep Vein Thrombosis
  • Post Thrombotic Syndrome
  • May-Thurner Syndrome
  • Hemodialysis/Arteriovenous Fistulae

• By Technology :

  • Iliac Vein Stent Technologies
  • Wallstent Technologies

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • MEA